Literature DB >> 12183762

Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate.

Anna L Schwartz1, John A Thompson, Nehal Masood.   

Abstract

PURPOSE/
OBJECTIVES: To examine the effect of exercise and methylphenidate on fatigue, functional ability, and cognitive function in patients with melanoma.
DESIGN: Pilot study with comparison to historic controls.
SETTING: University-based cancer center. SAMPLE: 12 patients with melanoma entered and completed the study. The mean age was 44 years.
METHOD: Eligible patients were recruited before their first dose of interferon-a (IFN-a). Patients were instructed to take 20 mg sustained-release methylphenidate every morning and follow an aerobic exercise program four days a week for 15-30 minutes. Measures included a 12-minute walk, the Schwartz Cancer Fatigue Scale, Trail Maker Forms A and B, Medical Outcomes Study 36 Short Form, body weight, and daily logs. Fatigue scores were compared to usual care historical controls with melanoma receiving only IFN-a. MAIN RESEARCH VARIABLES: Fatigue, functional ability, and cognitive function.
FINDINGS: 66% adhered to exercise and methylphenidate; all adhered to exercise. Fatigue was lower for the exercise and methylphenidate group than historic controls. Functional ability increased 6% for all patients and 9% for the exercise and methylphenidate group. Cognitive function was stable for the exercise and methylphenidate group. The exercise-only group showed marked cognitive slowing.
CONCLUSION: The combination of aerobic exercise and methylphenidate may have a positive effect on fatigue, cognitive function, and functional ability. A larger sample size and randomized trial is needed to more rigorously evaluate the results of exercise and methylphenidate alone or in combination. IMPLICATIONS FOR NURSING: Although further study is needed, a combination of exercise and methylphenidate may be a practical intervention for patients receiving IFN-a for melanoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183762     DOI: 10.1188/02.ONF.E85-E90

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  29 in total

1.  Factors associated with response to methylphenidate in advanced cancer patients.

Authors:  Sriram Yennurajalingam; J Lynn Palmer; Ray Chacko; Eduardo Bruera
Journal:  Oncologist       Date:  2011-01-31

2.  Management of Psychiatric Disease in Hepatitis C Treatment Candidates.

Authors:  Francis Lotrich
Journal:  Curr Hepat Rep       Date:  2010-04-06

Review 3.  Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults.

Authors:  Susan E Hardy
Journal:  Am J Geriatr Pharmacother       Date:  2009-02

4.  Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.

Authors:  Andrew H Miller
Journal:  Brain Behav Immun       Date:  2008-09-03       Impact factor: 7.217

Review 5.  Inflammation at the intersection of behavior and somatic symptoms.

Authors:  Michael R Irwin
Journal:  Psychiatr Clin North Am       Date:  2011-09

6.  Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial.

Authors:  Amanda R Moraska; Amit Sood; Shaker R Dakhil; Jeff A Sloan; Debra Barton; Pamela J Atherton; Jason J Suh; Patricia C Griffin; David B Johnson; Aneela Ali; Peter T Silberstein; Steven F Duane; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

Review 7.  Ameliorative effects of Tai Chi on cancer-related fatigue: a meta-analysis of randomized controlled trials.

Authors:  Shangjin Song; Jiahui Yu; Yi Ruan; Xuan Liu; Lijuan Xiu; Xiaoqiang Yue
Journal:  Support Care Cancer       Date:  2018-03-21       Impact factor: 3.603

8.  Cancer-Related Fatigue, Version 2.2015.

Authors:  Ann M Berger; Kathi Mooney; Amy Alvarez-Perez; William S Breitbart; Kristen M Carpenter; David Cella; Charles Cleeland; Efrat Dotan; Mario A Eisenberger; Carmen P Escalante; Paul B Jacobsen; Catherine Jankowski; Thomas LeBlanc; Jennifer A Ligibel; Elizabeth Trice Loggers; Belinda Mandrell; Barbara A Murphy; Oxana Palesh; William F Pirl; Steven C Plaxe; Michelle B Riba; Hope S Rugo; Carolina Salvador; Lynne I Wagner; Nina D Wagner-Johnston; Finly J Zachariah; Mary Anne Bergman; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2015-08       Impact factor: 11.908

Review 9.  Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.

Authors:  Andrew H Miller; Sonia Ancoli-Israel; Julienne E Bower; Lucile Capuron; Michael R Irwin
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

10.  Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study.

Authors:  Karen M Mustian; Jennifer J Griggs; Gary R Morrow; Anne McTiernan; Joseph A Roscoe; Christopher W Bole; James N Atkins; Brian F Issell
Journal:  Support Care Cancer       Date:  2006-02-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.